PRISMAP — building a European network for medical radionuclides
PRISMAP, the European medical radionuclides program, aims to revolutionize nuclear therapy and molecular imaging by providing immediate access to novel radionuclides for medical research. These advancements are crucial for improving outcomes in conditions like disseminated cancer. PRISMAP has established a network of leading European facilities, including nuclear reactors and radiochemical labs, to offer a wide range of radionuclides and support their development. Researchers can apply for access to these resources, with a selection panel choosing the most promising projects to drive innovation from research to patient care.